Tay-Sachs Disease: HEXA Gene Mutation and Pathogenic Mechanism

Tay-Sachs disease is caused by loss-of-function mutations in the HEXA gene (15q23-q24), encoding the α-subunit of β-hexosaminidase A (HexA). HexA is a lysosomal enzyme essential for GM2 ganglioside catabolism.

Molecular Pathogenesis

  1. HEXA mutations → absent/defective α-subunit → unstable HexA (αβ) dimer → <1% residual activity (classic infantile).
  2. GM2 ganglioside accumulates in neuronal lysosomes → membranous cytoplasmic bodies (MCBs).
  3. Neuronal dysfunction & death → progressive neurodegeneration.

Mutation Spectrum

  • Over 200 pathogenic variants reported: insertions, deletions, splice-site, missense, nonsense.
  • Allelic heterogeneity: Different mutations → different residual activity → phenotype spectrum (infantile, juvenile, late-onset).
  • Founder mutations in specific populations (see Article 161527).
  • Pseudodeficiency alleles (R247W, R249W): Reduce activity vs. artificial substrate (4-MUG) but not vs. natural GM2; benign.

Genotype-Phenotype Correlation

GenotypeResidual HexAPhenotype
Null / Null<1%Classic infantile
Null / Residual1–5%Juvenile
Residual / Residual5–15%Late-onset (LOTS)
Pseudodeficiency / PathogenicNormal (natural substrate)Asymptomatic carrier

Implications

  • Carrier testing: Must distinguish pseudodeficiency (DNA required).
  • Prenatal diagnosis: Enzyme assay on CVS/amniocytes + confirmatory sequencing.
  • Therapeutic development: Mutation-specific approaches (chaperones for misfolding mutations, read-through for nonsense, gene therapy for all).
  • GM2 activator deficiency (AB variant): GM2A mutations cause identical phenotype; test if HEXA negative.

The HEXA-GM2 axis exemplifies how a single enzymatic defect cascades into catastrophic neurological failure.

Genetic Disorders - Related Articles